[Cardiovascular disease and sexuality]

Area of Science:

• Cardiology
• Sexual Medicine

Background:

• Sexual activity is light to moderate exercise, posing minimal risk for most cardiovascular disease (CVD) patients.
• Patients with severe angina or heart failure may experience adverse events during sex.
• Sexual dysfunction is more prevalent in CVD patients due to atherosclerosis and endothelial dysfunction.

Purpose of the Study:

• To assess the risks and safety of sexual activity in patients with cardiovascular disease.
• To evaluate the use of phosphodiesterase type 5 (PDE-5) inhibitors in CVD patients with sexual dysfunction.
• To highlight contraindications and precautions regarding PDE-5 inhibitors and nitrates.

Main Methods:

• Review of existing literature and clinical guidelines.
• Risk stratification based on cardiovascular disease severity.
• Analysis of drug interactions, particularly PDE-5 inhibitors and nitrates.

Main Results:

• The absolute risk of cardiac events during sexual activity is very low for most CVD patients.
• PDE-5 inhibitors are safe for many CVD patients with sexual dysfunction, excluding those on nitrates.
• Concomitant use of PDE-5 inhibitors and nitrates is strictly contraindicated due to life-threatening hypotension risk.

Conclusions:

• Sexual activity can be safely managed in most CVD patients with appropriate risk assessment.
• Careful consideration of medication, especially PDE-5 inhibitors and nitrates, is crucial for patient safety.
• The Princeton Consensus Conference guidelines offer a framework for counseling CVD patients on sexual activity.